Treating vascular risk factors and maintaining vascular health: Is this the way towards successful cognitive ageing and preventing cognitive decline?

Postgraduate Medical Journal

Volumn 82, Issue 964, 2006, Pages 101-105

  Alagiakrishnan, K ^a,b   McCracken, P ^b   Feldman, H ^c  

^a GLENROSE REHABILITATION HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CHOLINESTERASE INHIBITOR; CYANOCOBALAMIN; DONEPEZIL; ENALAPRIL MALEATE; FOLIC ACID; GLUCOSE; HYDROCHLOROTHIAZIDE; MEVINOLIN; NICOTINIC ACID; NITRENDIPINE; PLACEBO; PRAVASTATIN; SELEGILINE;

ALZHEIMER DISEASE; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; EXERCISE; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; MIXED DEPRESSION AND DEMENTIA; PREVALENCE; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOCIAL ASPECT; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; BLOOD GLUCOSE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEMENTIA; DIET; EXERCISE; HORMONE REPLACEMENT THERAPY; HUMANS; INTERPERSONAL RELATIONS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; STRESS, PSYCHOLOGICAL; VASCULAR DISEASES;

EID: 33144485564     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2005.035030     Document Type: Review

References (54)

1. Brookmeyer R, Corrada MM, Curriero FC, et al. Survival following a diagnosis of Alzheimer's disease. Arch Neurol 2002;59:1764-7.
2. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337-42.
3. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA 1991;265:3255-64.
4. Guo Z, Fratiglioni L, Zhu L, et al. Occurrence and progression of dementia in community population aged 75 years and older. Relationship to antihypertensive medication use. Arch Neurol 1999;56:991-6.
5. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomized double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347-51.
6. Forette F, Seux ML, Staessen JA, et al for the Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in Europe (Syst-Eur) study. Arch Intern Med, 200214, 162:2046-52.
7. Lithell H, Hansson L, Skoog I, et al for the SCOPE study group. The study on cognition and prognosis in the elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J Hypertension 2004;22:1605-12.
8. Jacobson EJ, Salehmoghaddam S, Dorman JA, et al. The effect of blood pressure control on cognitive function (the FOCUS study). Am J Hypertens 2001;14:55A.
9. Wolozin B, Wellman W, Rousseau P, et al. Decreased prevalence of Alzheimer's disease associated with 3- hydroxy-3methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-43.
10. Jick H, Zornberg GL, Jick SS, et al. A. Statins and the risk of dementia. Lancet 2000;356:1627-31.
11. Yaffe K, Barrett-Connor E, Lin F, et al. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002;59:378-84.
12. Crisby M, Carlson LA, Winblad B. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2002;16:131-6.
13. Naidu A, Xu Q, Catalano R, et al. Secretion of apolipoprotein E by brain glia requires protein prenylation and is suppressed by statins. Brain Res 2002;958:100-11.
14. Fassbender K, Simon M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta- amyloid peptides Abeta 42 and Abeta 40 in vitro and vivo. Proc Natl Acad Sci U S A 2001;98:5856-61.
15. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002;59:223-7.
16. Hajjar I, Schumpert J, Hirth V, et al. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci, 2002;57:M414-18.
17. Rodriguez EG, Dodge HH, Birzescu MA, et al. Use of lipid lowering drugs in older adults with and without dementia: a community based epidemiological study. J Am Geriatr Sac 2002;50:1852-6.
18. Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002;52:346-50.
19. Shepherd J, Blauw GJ, Murphy MB, for the Prosper Study Group, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): randomized controlled trial. Lancet 2002;360:1623-30.
20. Vega GL, Weiner MF, Lipton AM, et al. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol 2003;60:510-15.
21. Floyd RA, Hensley K. Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol Aging 2002;23:795.
22. Grundman M, Delaney P. Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc 2002;61:191-202.
23. Riviere S, Birlouenz-Aragon I, Nourhasheni F, et al. Low plasma vitamin C in Alzheimer's patients despite an adequate diet. Int J Geriatr Psychiatry 1998;13:749-54.
24. Jimenez- Jimenez FJ, Molina JA, deBustos F, et al. Serum levels of beta carotene, alpha carotene and vitamin A in patients with Alzheimer's disease. Eur J Neurol 1999;6:495-7.
25. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease co-operative study. N Engl J Med 1997;336:1216-22.
26. Morris MC, Evans DA, Bienias JL, et al. Vitamin E and cognitive decline in older persons. Arch Neurol 2002;59:1125-32.
27. Peterson RC, Thomas RG, Ferris S, et al. Vitamin E and Donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2439-41.
28. Kruman II, Kumaravel TS, Lohani A, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models in Alzheimer's disease. J Neurosci 2002;22:1752-62.
29. Renvall MJ, Spindler AA, Ramsdell JW, et al. Nutritional status of free-living Alzheimer's patients. Am J Med Sci 1989;298:20-7.
30. Serot JM, Christmann D, Dubost T, et al. CSF folate levels are decreased in late-onset AD patients. J Neural Transm 2001;108:93-9.
31. Wang HX, Wahlin A, Basun H, et al. Vitamin B12 and folate in relation to the development of Alzheimer's disease. Neurology 2001;56:1188-94.
32. Leblhuber F, Walli J, Artner- Dworzak E, et al. Homocysteine and B vitamins in dementia. J Neural Transm 2000;107:1469-74.
33. Rodriquez G, Vitali P, Calvini P, et al. Hippocampal perfusion in mild Alzheimer's disease. Psychiatry Res 2000;100:65-74.
34. Vennerica A, Shanks HG, Murray AD. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport 2002;13:83-7.
35. Nakano S, Asada T, Matsuda H, et al. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J Nucl Med 2001;42:1441-5.
36. Mayor S. Regulatory authorities review use of galantamine in mild cognitive impairment. BMJ 2005;33:276.
37. Seeman TE, Singer BH, Rowe JW, et al. Price of adaption-allostatic load and its health consequences. MacArthur studies of successful aging. Arch Intern Med 1997;157:2259-68.
38. Liv J, Mori A. Stress, aging and brain oxidative damage. Neurochem Res 1999;24:11479-97.
39. Krishnan KR, Gadde KM. The pathophysiologic basis for late life depression. Imaging studies of the aging brain. Am J Geriatr Psychol 1996;4(suppl 1):S22-33.
40. Sheline YI, San Ghavi M, Mintum MA, et al. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999;19:5034-43.
41. Kalmijn S, Launder LJ, Ott A, et al. Dietary fat intake and the risk of incident dementia in the Rotterdam study. Ann Neurol 1997;42:776-82.
42. Kalmijn S, Feskens EJ, Launer LJ, et al. Polyunsaturated fatty acids, anti oxidants and cognitive function in very old men. Am J Epidemiol 1997;145:33-41.
43. Kalmijn S. Fatty acid intake and the risk of dementia and cognitive decline: a review of clinical and epidemiological studies. J Nutr Health Aging 2000;4:202-7.
44. Gradman TJ, Laws A, Thompson LW, et al. Verbal learning and/or memory improves with glycemic control in older subjects with non-insulin dependent diabetes mellitus. J Am Geriatr Soc 1993;41:1305-12.
45. Meneilly GS, Cheung E, Tessier D, et al. The effect of improved glycemic control on cognitive functions in the elderly patients with diabetes. J Gerontol A Biol Med Sci 1993;48:M117-21.
46. Laurin D, Verreault R, Lindsay J, et al. Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol 2001;38:498-504.
47. Colcombe SJ, Erickson KI, Raz N, et al. Aerobic fitness reduces brain loss in aging humans. J Gerontol A Biol Sci Med Sci 2003;58:M176-80.
48. Yaffe K, Barnes D, Nevitt M, et al. A prospective study of physical activity and cognitive decline in elderly women: women who walk. Arch Intern Med 2001;161:1703-8.
49. Wang HX, Karp A, Winbad B, et al. Late-life engagement in social and leisure activities is associated with a decreased risk of dementia: a longitudinal study from the Kungsholmen project. Am J Epidemiol 2002;155:1081-7.
50. Verghese J, Lipton RB, Katz MJ, et al. Leisure activities and the risk of dementia in the elderly. N Engl J Med 2003;348:2508-16.
51. Fratiglioni L, Paillard- Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 2004;3:343-53.
52. Meyer JS, Rogers RL, Mc Clintic K, et al. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc 1989;37:549-55.
53. Shumaker SA, Legault TC, Rapp SR, et al. Estrogen plus progestrin and the incidence of dementia and mild cognitive impairment in post menopausal women. JAMA 2003;289:2651-62.
54. Yaffe K, Krueger K, Cummings SR, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: The multiple outcomes of raloxifene evaluation (MORE) randomized trail. Am J Psychiatry 2005;162:683-90.